Dana Pizzuti Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

Dana Pizzuti is Chief Med and Dev Officer of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 28,507 shares of CRNX, which is worth approximately $1.54 Million. The most recent transaction as insider was on Oct 03, 2024, when has been sold 14,375 shares (Common Stock) at a price of $54.63 per share, resulting in proceeds of $785,306. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.5K

0% 3M change

382.27% 12M change

Total Value Held $1.54 Million

Dana Pizzuti Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 03 2024	SELL Open market or private sale	$785,306 $54.63 p/Share	14,375 Reduced 33.52%	28,507 Common Stock
Oct 03 2024	BUY Exercise of conversion of derivative security	$242,793 $16.89 p/Share	14,375 Added 25.11%	42,882 Common Stock
Jul 03 2024	SELL Open market or private sale	$645,006 $44.87 p/Share	14,375 Reduced 33.52%	28,507 Common Stock
Jul 03 2024	BUY Exercise of conversion of derivative security	$242,793 $16.89 p/Share	14,375 Added 25.11%	42,882 Common Stock
Jun 24 2024	SELL Open market or private sale	$434,434 $45.73 p/Share	9,500 Reduced 25.48%	27,786 Common Stock
Jun 24 2024	BUY Exercise of conversion of derivative security	$160,455 $16.89 p/Share	9,500 Added 20.31%	37,286 Common Stock
Apr 15 2024	SELL Open market or private sale	$639,256 $44.47 p/Share	14,375 Reduced 34.1%	27,786 Common Stock
Apr 15 2024	BUY Exercise of conversion of derivative security	$242,793 $16.89 p/Share	14,375 Added 25.43%	42,161 Common Stock
Mar 20 2024	SELL Open market or private sale	$668,291 $44.29 p/Share	15,089 Reduced 35.19%	27,786 Common Stock
Mar 20 2024	BUY Exercise of conversion of derivative security	$242,793 $16.89 p/Share	14,375 Added 27.19%	38,500 Common Stock
Mar 18 2024	SELL Payment of exercise price or tax liability	$15,675 $38.14 p/Share	411 Reduced 1.42%	28,500 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	23,000 Added 44.31%	28,911 Common Stock
Jan 03 2024	SELL Open market or private sale	$503,125 $35.0 p/Share	14,375 Reduced 70.86%	5,911 Common Stock
Jan 03 2024	BUY Exercise of conversion of derivative security	$242,793 $16.89 p/Share	14,375 Added 41.47%	20,286 Common Stock
Dec 21 2023	SELL Open market or private sale	$331,284 $34.57 p/Share	9,583 Reduced 61.85%	5,911 Common Stock
Dec 21 2023	BUY Exercise of conversion of derivative security	$161,856 $16.89 p/Share	9,583 Added 38.21%	15,494 Common Stock
Apr 05 2023	SELL Open market or private sale	$132,623 $16.15 p/Share	8,212 Reduced 64.6%	4,500 Common Stock
Apr 03 2023	SELL Payment of exercise price or tax liability	$68,522 $15.98 p/Share	4,288 Reduced 25.22%	12,712 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	4,500 Added 20.93%	17,000 Common Stock
Oct 10 2022	BUY Grant, award, or other acquisition	-	12,500 Added 50.0%	12,500 Common Stock

Dana Pizzuti

Chief Med and Dev Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Value

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX

Account